There are over 7,000 known rare diseases, collectively affecting more than 300 million people worldwide. Despite the word “rare,” these conditions are surprisingly common when taken together. They range from genetic disorders that appear at birth to neurological diseases that strike in adulthood, and the vast majority have no approved treatment.
What Counts as a Rare Disease
The definition depends on where you live. In the European Union, a disease is considered rare if it affects fewer than 5 in 10,000 people. In the United States, the threshold is any condition affecting fewer than 200,000 Americans at a given time. About 80% of rare diseases have a genetic origin, and 70% of them begin in childhood. Some affect millions of people globally, while others have been documented in just a single family.
Only about 5% of the nearly 10,000 identified rare diseases have an FDA-approved treatment. That means for the overwhelming majority, patients and families are managing symptoms without a targeted therapy.
Lysosomal Storage Disorders
One well-known group of rare diseases involves a malfunction in the cell’s waste-recycling system. Normally, tiny compartments inside your cells called lysosomes break down fats, sugars, and proteins so the body can reuse them. When the enzymes responsible for this cleanup are missing or defective, waste materials build up and damage organs over time.
Gaucher disease is the most common of these. A faulty gene leads to the accumulation of a fatty substance in cells of the liver, spleen, and bone marrow. This causes an enlarged liver and spleen, bone pain, easy bruising, and low blood counts. There are three types: type 1 affects the organs but spares the brain, while types 2 and 3 also damage the nervous system because a toxic byproduct builds up in brain cells.
Fabry disease results from a different enzyme deficiency in the same metabolic pathway. Fat accumulates in blood vessel walls, the kidneys, and the heart, eventually leading to stroke and kidney failure. Symptoms often start in childhood with burning pain in the hands and feet, but organ damage may not become apparent until adulthood.
Pompe disease is a glycogen storage disorder where the body can’t properly break down a complex sugar called glycogen. It accumulates in muscles, progressively weakening them. In infants, it can cause a dangerously enlarged heart. In adults, it tends to affect the muscles used for breathing and walking.
Rare Neurological Diseases
Huntington’s disease is caused by a specific type of genetic error called a repeat expansion. A short sequence of DNA building blocks in the huntingtin gene repeats far more times than it should. This leads to the production of a misshapen protein that gradually destroys nerve cells in the brain. Symptoms typically appear between ages 30 and 50, starting with subtle mood changes and coordination problems, then progressing to uncontrolled movements, cognitive decline, and difficulty swallowing. Because the mutation is dominant, a child of someone with Huntington’s has a 50% chance of inheriting it.
Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig’s disease, destroys the motor neurons that control voluntary movement. People gradually lose the ability to walk, speak, eat, and eventually breathe. Most cases appear between ages 40 and 70, and the disease progresses quickly. Researchers recently found a surprising genetic overlap between ALS and the mutation associated with Huntington’s disease, though this connection appears in a small fraction of patients.
Batten disease is a group of fatal nervous system disorders that primarily affect children. Waste products accumulate inside nerve cells, leading to seizures, vision loss, declining mental ability, and loss of motor skills. It is one of the most common neurodegenerative disorders in children, and most forms are fatal within a decade of symptom onset.
Ultra-Rare Conditions
Some conditions are so uncommon they’ve been documented in just a handful of people or a single family anywhere in the world. The Orphanet database, a major European reference for rare diseases, catalogs conditions where the total published evidence amounts to one family or one confirmed case. Examples include certain chromosome microduplication syndromes and extremely specific forms of amyloidosis, a disease where abnormal proteins fold incorrectly and deposit in organs.
These ultra-rare conditions pose enormous challenges. With so few patients, clinical trials are nearly impossible to organize, and pharmaceutical companies have little financial incentive to develop treatments. Patients often become their own advocates, connecting with researchers directly and sometimes traveling internationally to find a specialist who has seen even one similar case.
The Diagnostic Odyssey
Getting a diagnosis is one of the hardest parts of living with a rare disease. The average patient waits 5.6 years for an accurate diagnosis, a journey so grueling it has its own name: the diagnostic odyssey. During that time, patients typically see multiple specialists, receive incorrect diagnoses, and undergo treatments that don’t address the real problem.
This delay hits children especially hard. Rare diseases are responsible for 35% of all deaths in the first year of life, and 30% of children with a rare disease will not live to see their fifth birthday. Early and accurate diagnosis can be the difference between accessing a life-extending treatment and missing the window entirely.
Whole-genome sequencing has shortened the odyssey for some families. By reading a patient’s complete genetic code and comparing it against known disease-causing mutations, geneticists can sometimes pinpoint a diagnosis in weeks rather than years. But access to this testing remains uneven, particularly outside major medical centers and wealthy countries.
Why So Few Treatments Exist
The math works against rare disease patients. Developing a new drug costs hundreds of millions of dollars, and when the potential market is a few thousand people, the economics don’t add up without outside incentives. The Orphan Drug Act, passed in the U.S. in 1983, tried to fix this by offering tax credits, extended patent protections, and reduced regulatory fees to companies that develop treatments for rare conditions.
That law is still being refined. Recent legislation through the ORPHAN Cures Act adjusts how orphan drugs interact with Medicare’s drug price negotiation program, allowing a drug to hold more than one rare disease designation and changing when it becomes eligible for price negotiation. These tweaks aim to keep the financial incentives attractive enough that companies continue investing in rare disease research.
For the 95% of rare diseases that still lack an approved therapy, treatment is largely supportive: managing pain, preventing complications, and preserving function for as long as possible. Enzyme replacement therapies have transformed outcomes for some lysosomal storage disorders, and gene therapies are beginning to reach patients with a handful of genetic conditions. But for most rare diseases, the wait continues.